Some Leap Therapeutics (NASDAQ:LPTX) Shareholders Have Taken A Painful 83% Share Price Drop

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But serious investors should think long and hard about avoiding extreme losses. It must have been painful to be a Leap Therapeutics, Inc. (NASDAQ:LPTX) shareholder over the last year, since the stock price plummeted 83% in that time. That’d be a striking reminder about the importance of diversification. Leap Therapeutics hasn’t been listed for long, so although we’re wary of recent listings that perform poorly, it may still prove itself with time. Shareholders have had an even rougher run lately, with the share price down 33% in the last 90 days.

We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don’t have to lose the lesson.

View our latest analysis for Leap Therapeutics

Leap Therapeutics didn’t have any revenue in the last year, so it’s fair to say it doesn’t yet have a proven product (or at least not one people are paying for). We can’t help wondering why it’s publicly listed so early in its journey. Are venture capitalists not interested? As a result, we think it’s unlikely shareholders are paying much attention to current revenue, but rather speculating on growth in the years to come. It seems likely some shareholders believe that Leap Therapeutics has the funding to invent a new product before too long.

We think companies that have neither significant revenues nor profits are pretty high risk. You should be aware that there is always a chance that this sort of company will need to issue more shares to raise money to continue pursuing its business plan. While some such companies go on to make revenue, profits, and generate value, others get hyped up by hopeful naifs before eventually going bankrupt. Leap Therapeutics has already given some investors a taste of the bitter losses that high risk investing can cause.

When it reported in March 2019 Leap Therapeutics had minimal cash in excess of all liabilities consider its expenditure: just US$13m to be specific. So if it has not already moved to replenish reserves, we think the near-term chances of a capital raising event are pretty high. That probably explains why the share price is down 83% in the last year. You can see in the image below, how Leap Therapeutics’s cash levels have changed over time (click to see the values).

NasdaqGM:LPTX Historical Debt, June 14th 2019
NasdaqGM:LPTX Historical Debt, June 14th 2019

It can be extremely risky to invest in a company that doesn’t even have revenue. There’s no way to know its value easily. Would it bother you if insiders were selling the stock? I would feel more nervous about the company if that were so. You can click here to see if there are insiders selling.

A Different Perspective

Given that the market gained 3.2% in the last year, Leap Therapeutics shareholders might be miffed that they lost 83%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. The share price decline has continued throughout the most recent three months, down 33%, suggesting an absence of enthusiasm from investors. Given the relatively short history of this stock, we’d remain pretty wary until we see some strong business performance. You could get a better understanding of Leap Therapeutics’s growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

Of course Leap Therapeutics may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.